Clin Osteol 2011; 16(2): 43-51

Effect of denosumab therapy on selected bone quality markers in postmenopausal osteoporosisReview articles

P. Horák

Denosumab is a fully human IgG2 monoclonal antibody with highly specific and strong affinity for RANK ligand, which prevents for­ mation of osteoclasts, inhibits their function and shortens their survival. In phase II and III clinical trials, many aspects of the effect of denosumab were studied, including direct comparison with active comparator alendronate. The effect of denosumab on numerous parameters of bone quality was studied as well. Histological and histomorphometric studies confirmed maintenance of normal bone structure despite a strong antiresorptive effect of the drug with diminished formation of tetracycline bone labels. Analyses of the effect on hip structure and QCT of the forearm confirmed the effect of denosumab in regions with prevailing trabecular as well as compact bones. FEA analysis of QCT scans showed a significant improvement of strength at measured sites. The article describes the effect of denosumab on selected bone quality parameters.

Keywords: denosumab, bone quality, histomorphometry, HSA, FEA

Published: December 11, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Horák P. Effect of denosumab therapy on selected bone quality markers in postmenopausal osteoporosis. Osteologický bulletin. 2011;16(2):43-51.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Lewiecki EM. RANK ligand inhibition with denosumab for the management of osteoporosis. Exper Opin Biol Ther 2006;6:1041-1050. Go to original source...
    2. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal wo­ men with low bone mineral density. N Engl J Med 2006;354:821-831. Go to original source...
    3. Rosa J, Bayer M, Horák P, et al. Doporučené postupy pro diagnostiku a terapii post­ menopauzální osteoporózy II. Dodatek. Osteologický bulletin 2010;15:165-168.
    4. Lewiecki EM. Treatment of osteoporosis with denosumab. Maturitas 2010; 66:182-186. Go to original source...
    5. Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family mem­ ber RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999;96:3540-3545. Go to original source...
    6. Fata JE, Kong YY, Li J, et al. The osteoclast differentiation factor osteoprotegerin ligand is essential for mammary gland development. Cell 2000;103:41-50. Go to original source...
    7. Anderson DM, Maraskovsky E, Billingsley WL,et al. A homologue of the TNF re­ ceptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997;390:175-179. Go to original source...
    8. Boyle WJ, Simonet WS, Laceyet DL, el al. Osteoclast differentiation and activati­ on. Nature 2003;423:337-342. Go to original source...
    9. Bekker PJ, Holloway DL, Rasmussen AS, et al. Single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postme­ nopausal women. J Bone Miner Res 2004;19:1059-1066. Go to original source...
    10. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a li­ gand for osteoprotegerin/oscteoclastogenesis inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95:3597-3602. Go to original source...
    11. Lacey DL, Tan HL, Lu J, et al. Osteoprotegerin Ligand modulates murine osteoc­ last survival in vitro and in vivo. Am J Pathol 2000;157:435-448. Go to original source...
    12. Lewiecki EM, Miller PD, McClung MR, et al. Two-year treatment with denosu­ mab (AMG 162) in a randomized phase 2 study of postmenopausal women with low bone mineral density. J Bone Miner Res 2007;22:1832-1841. Go to original source...
    13. Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone den­ sity and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008;43:222-229. Go to original source...
    14. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab on bone mine­ ral density and bo 2008;93:2149-2157.
    15. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone tur postmenopausal women with low bone mass: A randomized, blinded, phase 3 trial. J Bone Miner Res 2009;24:153-161. Go to original source...
    16. Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mine­ ral density and bone turnover in postmenopausal dronate therapy. J Bone Miner Res 2010;25:72-81. Go to original source...
    17. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevent fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361:756-765. Go to original source...
    18. Felsenberg D, Boonen S. The bone quality framework: determinants of bone strength and their interrelat ment. Clin Ther 2005;27:1-11. Go to original source...
    19. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-795. Go to original source...
    20. Dempster DW. Primer on the Met Metabolism. 6'h ed. 2006; pp.7-11.
    21. Seeman E, Delmas PD. Bone quality - the material and strength and fragility. N Engl J Med 2006;354:2250-2261. Go to original source...
    22. Reid I, Benhamou C, Bolognese M, et al. Effects of Denosumab on bone gy and histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res 2009; 24(Suppl 1), S9, Abtract No. 1027.
    23. Brown JP, Dempster DW, Ding B, et al. Remodeling status in postm men who discontinued denosumab treatment. ASBMR annual meeting 2010; Abstract book, S22, Abstract No. 1069.
    24. Hologic, Inc. Emerging trends in dual energy x-ray absorptiometry. logic.com/sh/pdf/W_159_09-06_%20EmergTrendinDXA.pdf. Accessed November 20, 2010.
    25. Kaptoge S, Beck TJ, Reeve J, et al. Prediction of incident hip fracture risk by mur geometry variables measured by Hip Structural Analysis in the study of oste­ oporotic fractures. JBMR 2008;354:2250-2261. Go to original source...
    26. Li Z, Chines AA, Meredith MP. Statistical validation of surrogate endpoints: is bone density a valid surrogate for fracture? J Musculoskelet Neuronal Interact 2004;4:64-74.
    27. Cummings S, Yang Y, Vittinghoff E, et al. Increases in BMD on denosumab ex­ plain much ofthe reduction in fracture risk. J Bone Miner Res. 2009; 24(Suppl 1): S56.
    28. Beck TJ. Extending DXA beyond bone mineral density: understanding hip struc­ ture analysis. Curr Osteoporos Rep 2007;5:49-55. Go to original source...
    29. Beck TJ, Lewiecki EM, Miller PD, et al. Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate. J Clin Densitom 2008;11:351-359. Go to original source...
    30. Genant HK, Engelke K, Hanley DA, et al. Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. Bone 2010;47:131-139. Go to original source...
    31. Babuska I, Banerjee U, Osborn JE. Generalized Finite Element Methods: Main ideas, results, and perspective. Intern J Comput Met 2004;1:67-103. Go to original source...
    32. Keaveny T, McClung MR, Genant HK, et al. Denosumab improves both femoral and vertebral strength in women with osteoporosis: Results from the FREEDOM Trial. ASBMR annual meeting 2010; Abstract book, S31, Abstract No. 1099.
    33. Gever J. FDA questions denosumab safety in advisory meeting documents. Available at:, accessed February 27, 2011. http://www.medpagetoday.com/ProductAlert/Prescriptions/15486

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.